Sickle cell anaemia with crisis – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:23:59 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Sickle cell anaemia with crisis – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of the effectiveness of iloprost compared to a placebo for treating vaso-occlusive crises in adults with sickle cell disease https://clinicaltrials.eu/trial/study-of-the-effectiveness-of-iloprost-compared-to-a-placebo-for-treating-vaso-occlusive-crises-in-adults-with-sickle-cell-disease/ Wed, 29 Apr 2026 15:09:22 +0000 https://clinicaltrials.eu/trial/study-of-the-effectiveness-of-iloprost-compared-to-a-placebo-for-treating-vaso-occlusive-crises-in-adults-with-sickle-cell-disease/ This study focuses on individuals with Sickle Cell Disease, a condition where red blood cells become misshapen and can block blood flow. The investigation specifically looks at vaso-occlusive crisis, which is a painful episode caused by these misshapen cells blocking small blood vessels. The purpose of the study is to evaluate the effectiveness of iloprost in managing these painful episodes. Participants will receive either iloprost or a placebo through an infusion, which is a method of delivering fluids directly into a vein.

During the study, the treatment will be administered over a period of up to five days. The researchers will observe the impact of the medication on the amount of opioid, a type of strong pain medicine, required by patients during their time in the hospital. The total hospital stay for these episodes may last up to 21 days.

]]> Comparing morphine alone to morphine and lidocaine for pain relief in sickle cell anemia patients with vaso-occlusive crisis https://clinicaltrials.eu/trial/comparing-morphine-alone-to-morphine-and-lidocaine-for-pain-relief-in-sickle-cell-anemia-patients-with-vaso-occlusive-crisis/ Wed, 29 Apr 2026 15:08:23 +0000 https://clinicaltrials.eu/trial/comparing-morphine-alone-to-morphine-and-lidocaine-for-pain-relief-in-sickle-cell-anemia-patients-with-vaso-occlusive-crisis/ This study involves patients with sickle cell anaemia who experience a painful complication called a vaso-occlusive crisis, which occurs when blood flow is blocked in blood vessels, causing severe pain. The study will compare two different pain treatment approaches. One group of patients will receive morphine hydrochloride alone, which is a strong pain medication, while the other group will receive a combination of morphine hydrochloride and lidocaine hydrochloride, which is a local numbing medication. Both treatments will be given through a vein using a method called patient-controlled analgesia, which allows patients to control their own pain medication doses within safe limits set by doctors.

The purpose of the study is to find out if adding lidocaine hydrochloride to morphine hydrochloride can reduce the total amount of morphine needed to control pain during a vaso-occlusive crisis. The study is designed so that neither the patients nor the doctors will know which treatment each patient is receiving during the trial, which helps ensure fair results. Patients will be randomly assigned to receive either the combination treatment or morphine alone.

During the study, researchers will measure how much morphine each patient uses, track changes in pain levels using a pain rating scale, monitor certain substances in the blood that may indicate how the body is responding to treatment, and watch for any unwanted effects that morphine might cause. The study will help doctors understand whether combining these two medications provides better pain relief with less morphine compared to using morphine by itself.

]]> Study on the Safety and Effectiveness of CSL889 for Adults and Adolescents with Sickle Cell Disease During Painful Crises https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-csl889-for-adults-and-adolescents-with-sickle-cell-disease-during-painful-crises/ Wed, 29 Apr 2026 15:04:21 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-csl889-for-adults-and-adolescents-with-sickle-cell-disease-during-painful-crises/ This clinical trial is focused on studying sickle cell disease, a genetic condition that affects the red blood cells, leading to episodes of severe pain known as vaso-occlusive crises. The study will evaluate a treatment called CSL889, which is a form of hemopexin, human, a protein that may help manage these painful episodes. The treatment is given as a solution through an intravenous infusion, meaning it is delivered directly into the bloodstream through a vein.

The purpose of the study is to assess the safety and effectiveness of CSL889 in helping to resolve vaso-occlusive crises in people with sickle cell disease. Participants in the study will receive either the CSL889 treatment or a placebo, which is a solution that does not contain the active substance. The study will monitor how quickly the painful episodes resolve and will also track any side effects that may occur.

Participants will be involved in the study for a period of time during which they will receive multiple doses of the treatment. The study will also collect information on how the body processes the treatment, known as pharmacokinetics. This includes measuring the concentration of CSL889 in the blood at different times. The study aims to provide valuable information on whether CSL889 can be a safe and effective treatment option for managing vaso-occlusive crises in sickle cell disease.

]]> Study of Intranasal Sufentanil and Intravenous Morphine for Severe Sickle Cell Pain Crisis in Children https://clinicaltrials.eu/trial/study-of-intranasal-sufentanil-and-intravenous-morphine-for-severe-sickle-cell-pain-crisis-in-children/ Wed, 29 Apr 2026 14:25:59 +0000 https://clinicaltrials.eu/trial/study-of-intranasal-sufentanil-and-intravenous-morphine-for-severe-sickle-cell-pain-crisis-in-children/ This clinical trial is focused on studying the treatment of severe pain crises in children with sickle cell disease. Sickle cell disease is a genetic condition that affects the red blood cells, causing them to become misshapen and leading to painful episodes known as vaso-occlusive crises. The study will explore the effectiveness of a medication called sufentanil, which is administered through the nose, followed by the standard treatment of morphine given through a vein. The goal is to determine if this combination provides better pain relief compared to a placebo followed by morphine.

Participants in the study will receive either the intranasal sufentanil or a placebo, and then morphine will be administered as soon as possible. The study will monitor the level of pain relief at various time points, starting from 30 minutes after the initial treatment. The trial aims to see if the combination of sufentanil and morphine can offer quicker and more effective pain relief for children experiencing these severe pain episodes.

The study will also observe any side effects that may occur, such as low blood pressure, breathing difficulties, or nausea, and will assess the overall satisfaction with the pain management provided. The trial is designed to improve the understanding of how to best manage severe pain in children with sickle cell disease, potentially leading to better treatment options in the future.

]]> Study on Crovalimab for Preventing Painful Episodes in Sickle Cell Disease Patients https://clinicaltrials.eu/trial/study-on-crovalimab-for-preventing-painful-episodes-in-sickle-cell-disease-patients/ Wed, 29 Apr 2026 14:23:55 +0000 https://clinicaltrials.eu/trial/study-on-crovalimab-for-preventing-painful-episodes-in-sickle-cell-disease-patients/ This clinical trial is focused on studying Sickle Cell Disease, a genetic condition that affects the red blood cells, causing them to become misshapen and leading to various health complications. The study is evaluating a treatment called Crovalimab, which is being tested to see if it can help prevent painful episodes known as vaso-occlusive episodes (VOE) that occur in people with this disease. These episodes happen when the sickle-shaped cells block blood flow, causing pain and potential damage to organs.

The purpose of the study is to assess how effective and safe Crovalimab is compared to a placebo. Participants in the study will receive either Crovalimab or a placebo, which is a substance with no active medication, to compare the outcomes. Crovalimab is administered as a solution for injection or infusion, meaning it is given directly into the bloodstream through a vein or under the skin. The study will monitor participants over a period to observe any changes in the frequency and severity of their VOEs, as well as other health measures.

Throughout the study, researchers will collect information on how often participants experience VOEs, both at home and in medical facilities, and any changes in their overall health. The study will also look at other health indicators, such as changes in blood tests and the time it takes for a participant to experience their first VOE after starting the study. This information will help determine if Crovalimab is a beneficial treatment option for people with Sickle Cell Disease.

]]> Study on the Safety and Effects of Crovalimab for Treating Vaso-Occlusive Episodes in Sickle Cell Disease Patients https://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-crovalimab-for-treating-vaso-occlusive-episodes-in-sickle-cell-disease-patients/ Wed, 29 Apr 2026 14:23:51 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-crovalimab-for-treating-vaso-occlusive-episodes-in-sickle-cell-disease-patients/ This clinical trial is focused on studying Sickle Cell Disease (SCD), a genetic condition that affects the red blood cells, causing them to become misshapen and leading to various health complications. The study is investigating a treatment called Crovalimab, which is administered as a solution for injection or infusion. The purpose of the study is to evaluate the safety of Crovalimab compared to a placebo in managing acute uncomplicated vaso-occlusive episodes, which are painful events that occur when blood flow is blocked in small vessels.

Participants in the study will receive either Crovalimab or a placebo. The study will monitor the safety of the treatment by observing any adverse events, changes in vital signs, and any reactions related to the infusion. Additionally, the study will measure the levels of Crovalimab in the blood over time and assess how the drug interacts with the body, including its effects on specific biological markers. The study aims to understand how quickly patients experience improvement from their vaso-occlusive episodes and to check for any antibodies that might develop against the drug.

The trial is designed to gather information over a period of time, with the estimated completion date set for October 2025. Participants will be closely monitored throughout the study to ensure their safety and to collect data on the effectiveness of Crovalimab in treating Sickle Cell Disease. This research is important for developing new treatments that can help manage the symptoms and complications associated with this condition.

]]>